Nick Haggar of Sandoz to become new EGA President

Takes up the role on 8 October

The European Generic medicines Association (EGA) has named Sandoz’s Nick Haggar as the new incoming President of the industry body. He will take over from Gudbjorg Edda Eggertsdottir of Actavis on 8 October. He continues with his responsibilities as Head of Western Europe, Middle East and Africa at generics and biosimilars manufacturer Sandoz.

Haggar has worked in the pharmaceutical and healthcare industry for 27 years and holds an MBA from Cranfield School of Management.

He will speak about his vision for generic and biosimilar medicines on 8 October at the Industrial Policy Conference hosted by the EGA in Brussels, Belgium.

Founded in 1993, the EGA represents generic pharmaceutical companies and its subsidiaries throughout Europe.

You may also like

Manufacturing

Sandoz opens new packaging centre in Stryków, Poland

The generics division of Novartis has invested €42m in the project
Regulatory

EGA outlines priorities in TTIP negotiations between EU and US

Also calls on EU to agree to set up quality testing, pharmacovigilance systems and regulatory agency in Africa
Regulatory

Biosimilars need the same names as original biologics

Proper naming of biosimilars is key for patient access and safety, say delegates at WHO INN meeting
Pharmaceutical

EGA seeks EU-wide strategy to boost generic and biosimilar medicines sectors

Companies represented within the EGA provide more than 150,000 jobs in Europe
Media

Asia and Latin America will drive biosimilars growth in next decade, says Visiongain

Established players will focus on monoclonal antibodies and licensing deals
Ingredients

Sandoz begins clinical trial of biosimilar rituximab

Aims to demonstrate the bioequivalence of the monoclonal antibody
Regulatory

FDA approves first generic version of Lovenox

Sanofi-aventis has reservations about Sandoz drug for treating DVT
Subscribe now